Imperial College London

Dr Daphne Babalis

Faculty of MedicineSchool of Public Health

Director of Operations, Imperial Clinical Trials Unit



+44 (0)20 7594 3403d.babalis09




110Stadium HouseWhite City Campus





Daphne Babalis is the Director of Operations for the Imperial Clinical Trials Unit (ICTU), within the School of Public Health. She is a Chemistry graduate (Imperial College London) with a PhD in Clinical Trials and over 15 years experience in managing multi-centre clinical trials in a range of therapeutic areas within academia and the NHS.

Daphne oversees the ICTU Operations team and works closely with all Sections of the ICTU team including Statistics, QA and Clinical Data Systems. Her role includes oversight of the ICTU portfolio to ensure trials are conducted in accordance with clinical trial regulations and ICTU Standard Operating Procedures.



Kanagaratnam P, Kim MY, 2022, Ablation Versus Anti-arrhythmic Therapy for Reducing All Hospital Episodes from Recurrent Atrial Fibrillation (AVATAR-AF): a prospective, randomised, multi-centre, open label trial, Ep Europace, ISSN:1099-5129

Maher TM, Tudor VA, Saunders P, et al., 2022, Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial, The Lancet Respiratory Medicine, ISSN:2213-2600

Pugh J, Anjum A, Petropoulou K, et al., 2022, Increase in colonic PRopionate as a method of prEVENTing weight gain in adults aged 20-40 years (iPREVENT): A multi-centre, double-blind, randomised, parallel-group study to investigate the efficacy of inulin-propionate ester versus inulin (control) in the prevention of weight gain over 12 months, F1000research, Vol:11, ISSN:2046-1402, Pages:1-14

Moss B, Lammons W, Johnson S, et al., 2022, More than words: Parent, Patient and Public Involvement perspectives on language used by clinical researchers in neonatal care, Early Human Development, Vol:171, ISSN:0378-3782


Vergis N, Patel VC, Bogdanowicz K, et al., 2022, Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH), ELSEVIER, Pages:S34-S35, ISSN:0168-8278

More Publications